CRISPR Therapeutics recently announced its Q1 2025 earnings, reporting a 71% year-over-year revenue increase to $0.9 million, but also a wider net loss of $136 million. The basic and diluted loss per share rose to $1.58. Despite these mixed financial results, the company's stock rose 5.8% over the past month, aligning with the broader market's upward trend amid positive market sentiment fueled by recent trade agreements and high gains in major indexes. The financial results may have contributed some weight to price moves but were largely consistent with broader market trends. We've identified 1 weakness with CRISPR Therapeutics and understanding the impact should be part of your investment process.NasdaqGM:CRSP Earnings Per Share Growth as at May 2025 Uncover the next big thing with financially sound penny stocks that balance risk and reward. CRISPR Therapeutics' shares have experienced a 21.57% decline over the past three years, reflecting the challenges faced in consistent revenue generation and escalating net losses. Over the past year, the company has underperformed both the US Biotechs industry and the broader US market, which saw declines of 13.5% and a 7.7% gain respectively. This comparison suggests that despite recent market sentiment, CRISPR's long-term performance remains unfavorable relative to its peers. The company's earnings report highlights persistent unprofitability and increasing losses driven by a growing revenue base, which was reported at a revenue increase of 71% year-over-year for Q1 2025 to $0.9 million. Analysts forecast significant revenue growth of 60% annually, but challenges in turning profitable remain evident. The recent 5.8% rise in CRISPR's share price can be juxtaposed with a consensus analyst price target of US$81, suggesting optimism in future potential despite current financial hurdles. This discrepancy between the current trading price of US$34.25 and price target indicates room for significant upside, contingent on future financial and operational performance aligning with market expectations. Assess CRISPR Therapeutics' future earnings estimates with our detailed growth reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include NasdaqGM:CRSP. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
CRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 Million
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...